{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:22:46Z","timestamp":1760242966088,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semerg.2025.102451","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:14:35Z","timestamp":1738916075000},"page":"102451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-9958","authenticated-orcid":false,"given":"A.","family":"Moy\u00e1 Amengual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7355-423X","authenticated-orcid":false,"given":"A.","family":"Serrano-Cumplido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2025.102451_bib0375","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Defunciones seg\u00fan la Causa de Muerte A\u00f1o 2022. Datos provisionales. Disponible en: https:\/\/www.ine.es\/prensa\/edcm_2022.pdf"},{"key":"10.1016\/j.semerg.2025.102451_bib0380","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Defunciones seg\u00fan la Causa de Muerte. Primer semestre 2023 (datos provisionales) y a\u00f1o 2022 (datos definitivos). Disponible en: https:\/\/www.ine.es\/prensa\/edcm_2022_d.pdf"},{"key":"10.1016\/j.semerg.2025.102451_bib0385","first-page":"40","article-title":"Pathogenesis of atherosclerosis: A multifactorial process","volume":"7","author":"Singh","year":"2002","journal-title":"Exp Clin Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0390","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2025.102451_bib0395","doi-asserted-by":"crossref","first-page":"134","DOI":"10.31083\/j.rcm2405134","article-title":"Non-traditional risk factors as contributors to cardiovascular disease","volume":"24","author":"Wang","year":"2023","journal-title":"Rev Cardiovasc Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0405","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"History of discovery: Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.semerg.2025.102451_bib0410","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0415","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0420","first-page":"204","article-title":"C-reactive protein: How has JUPITER impacted clinical practice?","volume":"9","author":"Verma","year":"2009","journal-title":"Ochsner J."},{"key":"10.1016\/j.semerg.2025.102451_bib0425","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0430","article-title":"The effects of colchicine on lipoprotein(a) and oxidized phospholipid associated cardiovascular disease risk","author":"Mohammadnia","year":"2024","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0435","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-2275(20)42092-9","article-title":"Quantification of apo[a] and apoB in human atherosclerotic lesions","volume":"32","author":"Pepin","year":"1991","journal-title":"J Lipid Res."},{"key":"10.1016\/j.semerg.2025.102451_bib0440","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0445","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/CIRCULATIONAHA.119.044720","article-title":"Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: Results from the multicenter SCOT-HEART trial (Scottish Computed Tomography of the HEART)","volume":"141","author":"Williams","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2025.102451_bib0450","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): Actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0455","doi-asserted-by":"crossref","first-page":"99e112","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0460","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.recesp.2022.03.006","article-title":"Lipoprote\u00edna (a) en una selecci\u00f3n de hospitales de Andaluc\u00eda y Extremadura. \u00bfInfradiagnosticada e infrautilizada?","volume":"75","author":"Arrobas Velilla","year":"2022","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0465","first-page":"278","article-title":"Lipoprote\u00edna (a) es un factor predictor de no consecuci\u00f3n de objetivos de c-LDL en pacientes con cardiopat\u00eda isqu\u00e9mica cr\u00f3nica","volume":"36","author":"G\u00f3mez-Barrado","year":"2024","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.semerg.2025.102451_bib0470","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","article-title":"Understanding the ins and outs of lipoprotein(a) metabolism","volume":"33","author":"Boffa","year":"2022","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.semerg.2025.102451_bib0475","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels\u2014brief report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.semerg.2025.102451_bib0480","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein(a)","volume":"56","author":"Schmidt","year":"2016","journal-title":"J Lipid Res."},{"key":"10.1016\/j.semerg.2025.102451_bib0485","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a)","volume":"278","author":"Hancock","year":"2003","journal-title":"J Biol Chem."},{"key":"10.1016\/j.semerg.2025.102451_bib0490","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1160\/TH05-07-0505","article-title":"Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells","volume":"95","author":"Ho-Tin-No\u00e9","year":"2006","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.semerg.2025.102451_bib0495","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0500","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1741-7015-11-117","article-title":"Immunity, atherosclerosis and cardiovascular disease","volume":"11","author":"Frosteg\u00e5rd","year":"2013","journal-title":"BMC Medicine."},{"key":"10.1016\/j.semerg.2025.102451_bib0505","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11883-024-01215-5","article-title":"Lipoprotein (a)-related inflammatory imbalance: A novel horizon for the development of atherosclerosis","volume":"26","author":"Qin","year":"2024","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.semerg.2025.102451_bib0510","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/antiox11091741","article-title":"Low concentrations of oxidized phospholipids increase stress tolerance of endothelial cells","volume":"11","author":"Mauerhofer","year":"2022","journal-title":"Antioxidants."},{"key":"10.1016\/j.semerg.2025.102451_bib0515","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-021-00304-0","article-title":"Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study","volume":"8","author":"Pierini","year":"2021","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.semerg.2025.102451_bib0520","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.semerg.2025.102451_bib0525","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0530","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2025.102451_bib0535","first-page":"118249","article-title":"Prognostic value of elevated lipoprotein (a) concentration to predict atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients","volume":"395","author":"Shishikura","year":"2024","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.semerg.2025.102451_bib0540","first-page":"100350","article-title":"Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations","volume":"38","author":"Ciffone","year":"2024","journal-title":"Am Heart J Plus."},{"key":"10.1016\/j.semerg.2025.102451_bib0545","first-page":"243","article-title":"Consenso sobre lipoprote\u00edna (a) de la Sociedad Espa\u00f1ola de Arteriosclerosis. Revisi\u00f3n bibliogr\u00e1fica y recomendaciones para la pr\u00e1ctica cl\u00ednica","volume":"36","author":"Delgado-Lista","year":"2024","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.semerg.2025.102451_bib0550","doi-asserted-by":"crossref","first-page":"e002060","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart."},{"key":"10.1016\/j.semerg.2025.102451_bib0555","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MOL.0000000000000950","article-title":"Strategies for management of patients with elevated lipoprotein(a)","volume":"35","author":"Ellberg","year":"2024","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.semerg.2025.102451_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100885","article-title":"Lipoprotein(a) throughout life in women","author":"Corral","year":"2024","journal-title":"Am J Prev Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0565","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","article-title":"When should we measure lipoprotein (a)?","volume":"34","author":"Kostner","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0570","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.semerg.2025.102451_bib0575","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0580","first-page":"1279","article-title":"Elevated lipoprotein(a) in the middle-aged Polish population: Preliminary data on the genetic background","volume":"81","author":"Konieczy\u0144ska","year":"2023","journal-title":"Kardiol Pol."},{"key":"10.1016\/j.semerg.2025.102451_bib0585","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2022.07.009","article-title":"Long-term tracking and population characteristics of lipoprotein (a) in the Cardiovascular Risk in Young Finns Study","volume":"356","author":"Raitakari","year":"2022","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.semerg.2025.102451_bib0590","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"JACC."},{"key":"10.1016\/j.semerg.2025.102451_bib0595","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2025.102451_bib0600","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2025.102451_bib0605","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-2275(20)42092-9","article-title":"Quantification of apo[a] and apoB in human atherosclerotic lesions","volume":"32","author":"Pepin","year":"1991","journal-title":"J Lipid Res."},{"key":"10.1016\/j.semerg.2025.102451_bib0610","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.semerg.2025.102451_bib0615","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","article-title":"Elevated lipoprotein(a) and risk of atrial fibrillation. An observational and mendelian randomization study","volume":"79","author":"Mohammadi-Shemirani","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0620","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol\u2013mediated cardiovascular risk: A participant-level meta-analysis","author":"Bhatia","year":"2024","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2025.102451_bib0625","doi-asserted-by":"crossref","first-page":"e024870","DOI":"10.1161\/JAHA.121.024870","article-title":"Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: The atherosclerosis risk in communities study","volume":"11","author":"Obisesan","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.semerg.2025.102451_bib0630","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0635","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: Potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism."},{"key":"10.1016\/j.semerg.2025.102451_bib0640","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2025.102451_bib0645","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): Resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0650","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.xkme.2023.100648","article-title":"Lipoprotein(a) and the risk for recurrent atherosclerotic cardiovascular events among adults with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"5","author":"Poudel","year":"2023","journal-title":"Kidney Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0655","doi-asserted-by":"crossref","first-page":"118465","DOI":"10.1016\/j.atherosclerosis.2024.118489","article-title":"High lipoprotein(s) as a cause of chronic kidney disease: A population-based Mendelian randomization study","volume":"395","author":"Simony","year":"2024","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.semerg.2025.102451_bib0660","doi-asserted-by":"crossref","first-page":"e50415","DOI":"10.2196\/50415","article-title":"Relationship between lipoprotein(a), renal function indicators, and chronic kidney disease: Evidence from a large prospective cohort study","volume":"10","author":"Liu","year":"2024","journal-title":"JMIR Public Health Surveill."},{"key":"10.1016\/j.semerg.2025.102451_bib0665","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism."},{"issue":"8 suppl A","key":"10.1016\/j.semerg.2025.102451_bib0670","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/S0735-1097(23)03757-9","article-title":"Niacin treatment effective for reducing Lp(a) levels (Poster at ACC.23)","volume":"81","author":"Echeverry","year":"2023","journal-title":"JACC."},{"key":"10.1016\/j.semerg.2025.102451_bib0675","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2025.102451_bib0680","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0685","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein(a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.semerg.2025.102451_bib0690","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0695","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res."},{"key":"10.1016\/j.semerg.2025.102451_bib0700","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.semerg.2025.102451_bib0705","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis","volume":"29","author":"De Boer","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0710","doi-asserted-by":"crossref","first-page":"569e576","DOI":"10.1016\/j.amjcard.2017.03.255","article-title":"A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol","volume":"120","author":"Ballantyne","year":"2017","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.semerg.2025.102451_bib0715","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0720","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.semerg.2025.102451_bib0725","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.semerg.2025.102451_bib0730","doi-asserted-by":"crossref","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): The multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.semerg.2025.102451_bib0735","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5603\/cj.93062","article-title":"Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations","volume":"31","author":"Cui","year":"2024","journal-title":"Cardiol J."},{"key":"10.1016\/j.semerg.2025.102451_bib0740","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11739-020-02276-5","article-title":"Genetic and nutritional factors determining circulating levels of lipoprotein(a): Results of the \u00abMontignoso Study\u00bb","volume":"15","author":"Sereni","year":"2020","journal-title":"Intern Emerg Med."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:19:48Z","timestamp":1760213988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359325000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1138359325000048"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102451","relation":{},"ISSN":["1138-3593"],"issn-type":[{"type":"print","value":"1138-3593"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102451"}}